fashion -WSS

fashion

author：comprehensive 2025-09-06 03:33:10 - browse：78982

The FDA building -- First Opinion coverage from STAT — Adobe

A panel of expert advisers to the Food and Drug Administration on Friday voted in favor of expanding the use of CAR-T therapy in blood cancer, despite concerns about the powerful treatment’s side effects.

The group voted 11-0 that the benefits of Carvykti, a CAR-T medicine from Johnson & Johnson and Legend Biotech, outweighed its risk for patients with multiple myeloma whose disease has persisted despite initial treatment. The same panel voted 8-3 in favor of Abecma, from Bristol Myers Squibb and 2seventy Bio, for multiple myeloma patients who’ve received at least two lines of therapy. Currently both medicines are approved only for patients who have been treated for myeloma with four or more medications.

In clinical trials, each drug proved to significantly delay disease progression compared to standard therapy. But zooming in on the data, the FDA observed an alarming imbalance of deaths in the early months of both studies, finding that more patients in the CAR-T group died of myeloma or side effects than those receiving the standard of care.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Eye stem cell transplant could help restore vision in injured people

focus

WSS

Special counsel raises new conflict of interest concerns for De Oliveira's lawyer

FDA approves first treatment for ultra

The Biogen Aduhelm mess could happen again

Texas Medical Board asked to define abortion emergency exception

Surgery pushed Ben Carson to fame

Beware the threat of staffing cuts at the CDC

hotspot

fashion

focus

Duchenne breakthrough therapy leaves behind pioneering families

Medicare Advantage plans can’t deny care with AI, CMS warns

What does generative AI mean for health care? We asked experts

Cano Health’s bankruptcy is a warning for Medicare Advantage

Malaria cases in Florida and Texas: Here’s what you need to know

Beware the threat of staffing cuts at the CDC

Medicare details structure of new drug price negotiation program

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Drug repurposing or repositioning? The language matters

Gene therapy for Afghan refugees’ infant will be fully covered

knowledge

A neonatal nurse in a British hospital has been found guilty of killing 7 babies

340B reform proposal comes out of Senate working group

Eye stem cell transplant could help restore vision in injured people

What’s missing from the debate over nursing home staff minimums

Unique patient identifier: Experts argue the benefits, pitfalls

340B reform proposal comes out of Senate working group

focus

hotspot

focus

entertainment